Integrated Filing — IndAS



General information about company
Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 05-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 05-Aug-2025   17:00:00
End date and time of board meeting 05-Aug-2025   19:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 62683400000
Other income 790400000
Total income 63473800000
2 Expenses
(a) Cost of materials consumed 11266300000
(b) Purchases of stock-in-trade 7139500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -686500000
(d) Employee benefit expense 10830000000
(e) Finance costs 917600000
(f) Depreciation, depletion and amortisation expense 2989800000
(f) Other Expenses
1 Other expenses 17720400000 17720400000
2 Net (gain) / loss on foreign currency transactions -858700000 -858700000
Total other expenses 16861700000
Total expenses 49318400000
3 Total profit before exceptional items and tax 14155400000
4 Exceptional items 0
5 Total profit before tax 14155400000
6 Tax expense
7 Current tax 4908900000
8 Deferred tax -2968100000
9 Total tax expenses 1940800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 12214600000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 12214600000
17 Other comprehensive income net of taxes 1602200000
18 Total Comprehensive Income for the period 13816800000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 12190300000
Total profit or loss, attributable to non-controlling interests 24300000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 13773000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 43800000
21 Details of equity share capital
Paid-up equity share capital 913500000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 26.7
Diluted earnings (loss) per share from continuing operations 26.62
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 26.7
Diluted earnings (loss) per share from continuing and discontinued operations 26.62
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1.tThe above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 05, 2025. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. n n2.tThe Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. U.S.A., Lupin Australia Pty Limited Australia, Nanomi B.V. Netherlands, Pharma Dynamics Proprietary Limited South Africa, Hormosan Pharma GmbH Germany, Multicare Pharmaceuticals Philippines Inc. Philippines, Lupin Atlantis Holdings SA Switzerland, Lupin Healthcare UK Limited U.K., Lupin Pharma Canada Limited Canada, Generic Health Pty Limited Australia, Lupin Mexico S.A. de C.V. Mexico, Lupin Philippines Inc. Philippines, Lupin Diagnostics Limited, India, Generic Health SDN. BHD., Malaysia, Lupin Inc., U.S.A., Laboratorios Grin S.A. de C.V. Mexico, Medquimica Industria Farmaceutica LTDA Brazil, Novel Laboratories, Inc. U.S.A., Lupin Research Inc. U.S.A., Lupin Management Inc. U.S.A, Lupin Europe GmbH Germany, Lupin Biologics Limited India, Lupin Oncology Inc. U.S.A, Lupin Digital Health Limited India, Avenue Coral Springs LLC U.S.A., Southern Cross Pharma Pty Ltd Australia, Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India, Lupin Manufacturing Solutions Limited India, Medisol S.A.S. France, Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05, 2024, Lupin NZ Ltd. New Zealand w.e.f. August 08, 2024, Lupinlife Consumer Healthcare Limited India w.e.f. March 08, 2025, Renascience Pharma Limited U.K. w.e.f. April 02, 2025 and a joint venture, YL Biologics Limited Japan. n n3.tThe Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. n n4.tDuring the quarter ended June 30, 2025, the Company through its wholly owned step down subsidiary, Lupin Healthcare UK Limited, acquired 100% equity share capital of Renascience Pharma Limited, U.K. for a consideration of Rs. 1,361.6 million GBP 12.3 million. Currently, the purchase consideration has been allocated on a provisional basis based on managements estimates. n n5.tDuring the quarter ended June 30, 2025, 151,078 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up share capital by Rs. 0.3 million and securities premium account by Rs. 146.1 million. n n n6.tDuring the year ended March 31, 2025, the Group has made a provision of Rs. 1,441.2 million USD 17.0 million respectively towards ongoing disputes. n n7.tDuring the quarter ended June 30, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. n n8.tDuring the quarter and year ended March 31, 2025, the Group has recognised an impairment charge of Rs. 1,135.3 milion and Rs. 1,209.0 milion respectively related certain property, plant and equipment, capital work in progress, intangible assets, intangible assets under development and goodwill. n n9.tThe figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended December 31, 2024. The year to date figures up to the third quarter ended December 31, 2024 were only subject to Limited Review and not audited. Review and not audited. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 62364100000 62364100000
2 Others 322800000 322800000
3 Less: Inter segment Assets 0 0
4 Less: Inter segment Liabilities 0 0
Total Segment Revenue 62686900000
Less: Inter segment revenue 3500000 3500000
Revenue from operations 62683400000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 14578400000 14578400000
2 Others -423000000 -423000000
3 Less: Inter segment Assets 0 0
4 Less: Inter segment Liabilities 0 0
Total Profit before tax 14155400000
i. Finance cost 0 0
ii. Other Unallocable Expenditure net off Unallocable income 0 0
Profit before tax 14155400000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 318909900000 318909900000
2 Others 2229400000 2229400000
3 Less: Inter segment Assets -3522700000 -3522700000
4 Less: Inter segment Liabilities 0 0
Total Segment Asset 317616600000 317616600000
Un-allocable Assets 0 0
Net Segment Asset 317616600000 317616600000
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 129854800000 129854800000
2 Others 3070000000 3070000000
3 Less: Inter segment Assets 0 0
4 Less: Inter segment Liabilities -2115800000 -2115800000
Total Segment Liabilities 130809000000 130809000000
Un-allocable Liabilities 0 0
Net Segment Liabilities 130809000000 130809000000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss -103500000 -103500000
Total Amount of items that will not be reclassified to profit and loss -103500000
2 Income tax relating to items that will not be reclassified to profit or loss -36200000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 1694900000 1694900000
Total Amount of items that will be reclassified to profit and loss 1694900000
4 Income tax relating to items that will be reclassified to profit or loss 25400000
5 Total Other comprehensive income 1602200000